Phase I Clinical Trial and Pharmacokinetic Evaluation of Acodazole (NSC 305884), an Imidazoquinoline Derivative with Electrophysiological Effects on the Heart

Donald L. Trump, Kendra D. Tutsch, James K.V. Willson, Scott Remick, Kris Simon, Dona Alberti, Jean Grem, Jim Koeller, Douglass C. Tormey

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Acodazole (NSC 305844) is a synthetic imidazoquinoline which has antimicrobial as well as antineoplastic properties. A Phase I trial of acodazole administered as a 1-h i.v. infusion once weekly x 4 was conducted. Mild to moderate nausea and vomiting and moderate burning and erythema at the infusion site were the only toxicities seen among 33 patients treated over 51 courses at doses between 20 mg/m2/week and 888 mg/m2. The first patient treated at 1184 mg/m2 developed an irregular pulse and was found to have a prolonged cardiac output interval (Q-T1) on electrocardiogram and polymorphic ventricular tachycardia (“torsades des pointes”). Careful study of five additional patients treated according to a modified schedule (340 mg/m2 week one, 500 mg/m2 week 2, 666 mg/m2 week 3, and 888 mg/m2 week 4) revealed 20% or greater Q-T1 prolongation after 20 of 27 treatments; Q-T1 prolongation had resolved 24–36 h after each infusion. Q-T1 prolongation occurred at all dose levels; no ventricular arrhythmias occurred. Acodazole was cleared with a long t1/2(20.7 h) primarily by nonrenal mechanisms. No alterations in peak plasma levels or excretion were seen in the patients in whom Q-T1 prolongation was detected. No antitumor activity was seen. Further development of acodazole will require delineation of pharmacological means of surppressing this Q-T1 prolongation.

Original languageEnglish (US)
Pages (from-to)3895-3900
Number of pages6
JournalCancer Research
Volume47
Issue number14
StatePublished - Jul 1987

Fingerprint

Clinical Trials, Phase I
Pharmacokinetics
Erythema
Ventricular Tachycardia
Cardiac Output
Antineoplastic Agents
Nausea
Vomiting
Pulse
Cardiac Arrhythmias
Appointments and Schedules
Electrocardiography
Pharmacology
acodazole
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Trump, D. L., Tutsch, K. D., Willson, J. K. V., Remick, S., Simon, K., Alberti, D., ... Tormey, D. C. (1987). Phase I Clinical Trial and Pharmacokinetic Evaluation of Acodazole (NSC 305884), an Imidazoquinoline Derivative with Electrophysiological Effects on the Heart. Cancer Research, 47(14), 3895-3900.

Phase I Clinical Trial and Pharmacokinetic Evaluation of Acodazole (NSC 305884), an Imidazoquinoline Derivative with Electrophysiological Effects on the Heart. / Trump, Donald L.; Tutsch, Kendra D.; Willson, James K.V.; Remick, Scott; Simon, Kris; Alberti, Dona; Grem, Jean; Koeller, Jim; Tormey, Douglass C.

In: Cancer Research, Vol. 47, No. 14, 07.1987, p. 3895-3900.

Research output: Contribution to journalArticle

Trump, DL, Tutsch, KD, Willson, JKV, Remick, S, Simon, K, Alberti, D, Grem, J, Koeller, J & Tormey, DC 1987, 'Phase I Clinical Trial and Pharmacokinetic Evaluation of Acodazole (NSC 305884), an Imidazoquinoline Derivative with Electrophysiological Effects on the Heart', Cancer Research, vol. 47, no. 14, pp. 3895-3900.
Trump, Donald L. ; Tutsch, Kendra D. ; Willson, James K.V. ; Remick, Scott ; Simon, Kris ; Alberti, Dona ; Grem, Jean ; Koeller, Jim ; Tormey, Douglass C. / Phase I Clinical Trial and Pharmacokinetic Evaluation of Acodazole (NSC 305884), an Imidazoquinoline Derivative with Electrophysiological Effects on the Heart. In: Cancer Research. 1987 ; Vol. 47, No. 14. pp. 3895-3900.
@article{3120d05aa0684209a6d529c2a8c86e89,
title = "Phase I Clinical Trial and Pharmacokinetic Evaluation of Acodazole (NSC 305884), an Imidazoquinoline Derivative with Electrophysiological Effects on the Heart",
abstract = "Acodazole (NSC 305844) is a synthetic imidazoquinoline which has antimicrobial as well as antineoplastic properties. A Phase I trial of acodazole administered as a 1-h i.v. infusion once weekly x 4 was conducted. Mild to moderate nausea and vomiting and moderate burning and erythema at the infusion site were the only toxicities seen among 33 patients treated over 51 courses at doses between 20 mg/m2/week and 888 mg/m2. The first patient treated at 1184 mg/m2 developed an irregular pulse and was found to have a prolonged cardiac output interval (Q-T1) on electrocardiogram and polymorphic ventricular tachycardia (“torsades des pointes”). Careful study of five additional patients treated according to a modified schedule (340 mg/m2 week one, 500 mg/m2 week 2, 666 mg/m2 week 3, and 888 mg/m2 week 4) revealed 20{\%} or greater Q-T1 prolongation after 20 of 27 treatments; Q-T1 prolongation had resolved 24–36 h after each infusion. Q-T1 prolongation occurred at all dose levels; no ventricular arrhythmias occurred. Acodazole was cleared with a long t1/2(20.7 h) primarily by nonrenal mechanisms. No alterations in peak plasma levels or excretion were seen in the patients in whom Q-T1 prolongation was detected. No antitumor activity was seen. Further development of acodazole will require delineation of pharmacological means of surppressing this Q-T1 prolongation.",
author = "Trump, {Donald L.} and Tutsch, {Kendra D.} and Willson, {James K.V.} and Scott Remick and Kris Simon and Dona Alberti and Jean Grem and Jim Koeller and Tormey, {Douglass C.}",
year = "1987",
month = "7",
language = "English (US)",
volume = "47",
pages = "3895--3900",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Phase I Clinical Trial and Pharmacokinetic Evaluation of Acodazole (NSC 305884), an Imidazoquinoline Derivative with Electrophysiological Effects on the Heart

AU - Trump, Donald L.

AU - Tutsch, Kendra D.

AU - Willson, James K.V.

AU - Remick, Scott

AU - Simon, Kris

AU - Alberti, Dona

AU - Grem, Jean

AU - Koeller, Jim

AU - Tormey, Douglass C.

PY - 1987/7

Y1 - 1987/7

N2 - Acodazole (NSC 305844) is a synthetic imidazoquinoline which has antimicrobial as well as antineoplastic properties. A Phase I trial of acodazole administered as a 1-h i.v. infusion once weekly x 4 was conducted. Mild to moderate nausea and vomiting and moderate burning and erythema at the infusion site were the only toxicities seen among 33 patients treated over 51 courses at doses between 20 mg/m2/week and 888 mg/m2. The first patient treated at 1184 mg/m2 developed an irregular pulse and was found to have a prolonged cardiac output interval (Q-T1) on electrocardiogram and polymorphic ventricular tachycardia (“torsades des pointes”). Careful study of five additional patients treated according to a modified schedule (340 mg/m2 week one, 500 mg/m2 week 2, 666 mg/m2 week 3, and 888 mg/m2 week 4) revealed 20% or greater Q-T1 prolongation after 20 of 27 treatments; Q-T1 prolongation had resolved 24–36 h after each infusion. Q-T1 prolongation occurred at all dose levels; no ventricular arrhythmias occurred. Acodazole was cleared with a long t1/2(20.7 h) primarily by nonrenal mechanisms. No alterations in peak plasma levels or excretion were seen in the patients in whom Q-T1 prolongation was detected. No antitumor activity was seen. Further development of acodazole will require delineation of pharmacological means of surppressing this Q-T1 prolongation.

AB - Acodazole (NSC 305844) is a synthetic imidazoquinoline which has antimicrobial as well as antineoplastic properties. A Phase I trial of acodazole administered as a 1-h i.v. infusion once weekly x 4 was conducted. Mild to moderate nausea and vomiting and moderate burning and erythema at the infusion site were the only toxicities seen among 33 patients treated over 51 courses at doses between 20 mg/m2/week and 888 mg/m2. The first patient treated at 1184 mg/m2 developed an irregular pulse and was found to have a prolonged cardiac output interval (Q-T1) on electrocardiogram and polymorphic ventricular tachycardia (“torsades des pointes”). Careful study of five additional patients treated according to a modified schedule (340 mg/m2 week one, 500 mg/m2 week 2, 666 mg/m2 week 3, and 888 mg/m2 week 4) revealed 20% or greater Q-T1 prolongation after 20 of 27 treatments; Q-T1 prolongation had resolved 24–36 h after each infusion. Q-T1 prolongation occurred at all dose levels; no ventricular arrhythmias occurred. Acodazole was cleared with a long t1/2(20.7 h) primarily by nonrenal mechanisms. No alterations in peak plasma levels or excretion were seen in the patients in whom Q-T1 prolongation was detected. No antitumor activity was seen. Further development of acodazole will require delineation of pharmacological means of surppressing this Q-T1 prolongation.

UR - http://www.scopus.com/inward/record.url?scp=0023263195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023263195&partnerID=8YFLogxK

M3 - Article

C2 - 3594447

AN - SCOPUS:0023263195

VL - 47

SP - 3895

EP - 3900

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 14

ER -